K. Blennow, M. De-leon, and H. Zetterberg, Alzheimer's disease, The Lancet, vol.368, issue.9533, pp.387-403, 2006.
DOI : 10.1016/S0140-6736(06)69113-7
URL : https://hal.archives-ouvertes.fr/hal-01098836

E. Corder, A. Saunders, W. Strittmatter, D. Schmechel, P. Gaskell et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, vol.261, issue.5123, pp.921-924, 1993.
DOI : 10.1126/science.8346443

D. Holtzman, J. Herz, and G. Bu, Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, p.6312, 2012.
DOI : 10.1101/cshperspect.a006312
URL : http://perspectivesinmedicine.cshlp.org/content/2/3/a006312.full.pdf

J. Castellano, J. Kim, F. Stewart, H. Jiang, R. Demattos et al., Human apoE Isoforms Differentially Regulate Brain Amyloid-?? Peptide Clearance, Science Translational Medicine, vol.330, issue.6012, pp.89-57, 2011.
DOI : 10.1126/science.1197623
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192364/pdf

P. Verghese, J. Castellano, K. Garai, Y. Wang, H. Jiang et al., ApoE influences amyloid-?? (A??) clearance despite minimal apoE/A?? association in physiological conditions, Proceedings of the National Academy of Sciences, vol.98, issue.15, pp.1807-1823, 2013.
DOI : 10.1073/pnas.151261398
URL : http://www.pnas.org/content/110/19/E1807.full.pdf

K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nature Reviews Neurology, vol.359, issue.3, pp.131-175, 2010.
DOI : 10.1016/j.bbadis.2004.09.008

N. Mattsson, P. Insel, M. Donohue, S. Landau, W. Jagust et al., Independent information from cerebrospinal fluid amyloid-?? and florbetapir imaging in Alzheimer's disease, Brain, vol.138, issue.3, pp.772-83, 2015.
DOI : 10.1093/brain/awu367
URL : https://academic.oup.com/brain/article-pdf/138/3/772/13798965/awu367.pdf

S. Palmqvist, N. Mattsson, and O. Hansson, Cerebrospinal fluid analysis detects cerebral amyloid-?? accumulation earlier than positron emission tomography, Brain, vol.139, issue.4, pp.1226-1262, 2016.
DOI : 10.1093/brain/aww015
URL : https://academic.oup.com/brain/article-pdf/139/4/1226/17348994/aww015.pdf

K. Blennow, N. Mattsson, M. Scholl, O. Hansson, and H. Zetterberg, Amyloid biomarkers in Alzheimer's disease, Trends in Pharmacological Sciences, vol.36, issue.5, pp.297-309, 2015.
DOI : 10.1016/j.tips.2015.03.002

D. Galasko, L. Chang, R. Motter, C. Clark, J. Kaye et al., High Cerebrospinal Fluid Tau and Low Amyloid ??42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype, Archives of Neurology, vol.55, issue.7, pp.937-982, 1998.
DOI : 10.1001/archneur.55.7.937

T. Sunderland, N. Mirza, K. Putnam, G. Linker, D. Bhupali et al., Cerebrospinal fluid ??-amyloid1???42 and tau in control subjects at risk for Alzheimer???s disease: The effect of APOE ??4 allele, Biological Psychiatry, vol.56, issue.9, pp.670-676, 2004.
DOI : 10.1016/j.biopsych.2004.07.021

L. Shaw, H. Vanderstichele, M. Knapik-czajka, C. Clark, P. Aisen et al., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Annals of Neurology, vol.55, issue.4, pp.403-416, 2009.
DOI : 10.1002/ana.21610
URL : http://onlinelibrary.wiley.com/doi/10.1002/ana.21610/pdf

R. Lautner, S. Palmqvist, N. Mattsson, U. Andreasson, A. Wallin et al., Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease, JAMA Psychiatry, vol.71, issue.10, pp.1183-91, 2014.
DOI : 10.1001/jamapsychiatry.2014.1060

J. Prince, H. Zetterberg, N. Andreasen, J. Marcusson, and K. Blennow, APOE ??4 allele is associated with reduced cerebrospinal fluid levels of A??42, Neurology, vol.62, issue.11, pp.2116-2124, 2004.
DOI : 10.1212/01.WNL.0000128088.08695.05

C. Schipke, F. Jessen, S. Teipel, C. Luckhaus, J. Wiltfang et al., Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid, J Alzheimers Dis, vol.26, pp.255-62, 2011.

J. Kuhlmann, U. Andreasson, J. Pannee, M. Bjerke, E. Portelius et al., CSF A?? 1???42 ??? an excellent but complicated Alzheimer's biomarker ??? a route to standardisation, Clinica Chimica Acta, vol.467, pp.27-33, 2017.
DOI : 10.1016/j.cca.2016.05.014

M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsater et al., Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid, International Journal of Alzheimer's Disease, vol.309, issue.6955, p.986310, 2010.
DOI : 10.1258/acb.2009.008232
URL : https://doi.org/10.4061/2010/986310

N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin et al., Cerebrospinal Fluid ??-Amyloid(1-42) in Alzheimer Disease, Archives of Neurology, vol.56, issue.6, pp.673-80, 1999.
DOI : 10.1001/archneur.56.6.673
URL : http://archneur.jamanetwork.com/data/journals/neur/6466/noc7877.pdf

A. Olsson, H. Vanderstichele, N. Andreasen, D. Meyer, G. Wallin et al., Simultaneous Measurement of ??-Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology, Clinical Chemistry, vol.51, issue.2, pp.336-381, 2005.
DOI : 10.1373/clinchem.2004.039347

J. Morris, C. Roe, C. Xiong, A. Fagan, A. Goate et al., predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging, Annals of Neurology, vol.164, issue.1, pp.122-153, 2010.
DOI : 10.1212/01.WNL.0000055875.26908.24
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830375/pdf

P. Insel, N. Mattsson, M. Donohue, R. Mackin, P. Aisen et al., The transitional association between ??-amyloid pathology and regional brain atrophy, Alzheimer's & Dementia, vol.11, issue.10, pp.1171-1180, 2015.
DOI : 10.1016/j.jalz.2014.11.002
URL : https://doi.org/10.1016/j.jalz.2014.11.002

P. Insel, N. Mattsson, R. Mackin, M. Scholl, R. Nosheny et al., Accelerating rates of cognitive decline and imaging markers associated with ??-amyloid pathology, Neurology, vol.86, issue.20, pp.1887-96, 2016.
DOI : 10.1212/WNL.0000000000002683
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873684/pdf

N. Mattsson, P. Insel, R. Nosheny, D. Tosun, J. Trojanowski et al., Emerging ??-Amyloid Pathology and Accelerated Cortical Atrophy, JAMA Neurology, vol.71, issue.6, pp.725-759, 2014.
DOI : 10.1001/jamaneurol.2014.446
URL : http://archneur.jamanetwork.com/data/journals/neur/930301/noi140019.pdf

N. Mattsson, P. Insel, M. Donohue, W. Jagust, R. Sperling et al., Predicting Reduction of Cerebrospinal Fluid ??-Amyloid 42 in Cognitively Healthy Controls, JAMA Neurology, vol.72, issue.5, pp.554-60, 2015.
DOI : 10.1001/jamaneurol.2014.4530

R. Caselli, A. Dueck, D. Osborne, M. Sabbagh, D. Connor et al., ??4 Effect, New England Journal of Medicine, vol.361, issue.3, pp.255-63, 2009.
DOI : 10.1056/NEJMoa0809437